1
40
1
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1517/14712598.2010.487061" target="_blank" rel="noreferrer noopener">http://doi.org/10.1517/14712598.2010.487061</a>
Pages
1105–1112
Issue
7
Volume
10
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Efficacy and safety of ustekinumab and etanercept for the treatment of psoriasis.
Publisher
An entity responsible for making the resource available
Expert opinion on biological therapy
Date
A point or period of time associated with an event in the lifecycle of the resource
2010
2010-07
Subject
The topic of the resource
Humans; Treatment Outcome; Severity of Illness Index; Risk Assessment; Evidence-Based Medicine; Patient Selection; Ustekinumab; Antibodies; Anti-Inflammatory Agents/adverse effects/*therapeutic use; Etanercept; Immunoglobulin G/adverse effects/*therapeutic use; Immunosuppressive Agents/adverse effects/*therapeutic use; Psoriasis/*drug therapy/immunology; Receptors; Humanized; Monoclonal; Monoclonal/adverse effects/*therapeutic use; Tumor Necrosis Factor/*therapeutic use
Creator
An entity primarily responsible for making the resource
Uhlenhake Elizabeth E; Feldman Steven R
Description
An account of the resource
IMPORTANCE OF THE FIELD: TNF-alpha inhibitors such as etanercept have been used for psoriasis for years. A fairly well defined efficacy and safety profile has developed. A new biologic agent, ustekinumab, an IL-12 and IL-23 inhibitor, has recently been released in the US for the treatment of moderate-to-severe psoriasis. The purpose of this article is to compare the efficacy and safety profiles of ustekinumab and etanercept. AREAS COVERED IN THIS REVIEW: We examined safety and efficacy data regarding ustekinumab and etanercept from clinical reports, a head-to-head trial, review articles, and databases and registries from the last 20 years. WHAT THE READER WILL GAIN: Evidence is reviewed about the efficacy for the treatment of psoriasis as well as the safety profiles for both agents, ustekinumab and etanercept. TAKE HOME MESSAGE: Both drugs have data to confirm efficacy and safety in patients with moderate-to-severe psoriasis in the short-term. The limited long-term data on the safety profile of ustekinumab requires careful judgment on the clinician's part, weighing well-defined benefits and potential unknown risks.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1517/14712598.2010.487061" target="_blank" rel="noreferrer noopener">10.1517/14712598.2010.487061</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
2010
Anti-Inflammatory Agents/adverse effects/*therapeutic use
Antibodies
Etanercept
Evidence-Based Medicine
Expert opinion on biological therapy
Feldman Steven R
Humanized
Humans
Immunoglobulin G/adverse effects/*therapeutic use
Immunosuppressive Agents/adverse effects/*therapeutic use
Monoclonal
Monoclonal/adverse effects/*therapeutic use
Patient Selection
Psoriasis/*drug therapy/immunology
Receptors
Risk Assessment
Severity of Illness Index
Treatment Outcome
Tumor Necrosis Factor/*therapeutic use
Uhlenhake Elizabeth E
Ustekinumab